Medlab Clinical () has completed the first stage medical trials of its NanaBis product, and is encouraged by its progress with US and European medical registration administrations.
CEO Sean Hall distinguishes Medlab Clinical () from other "pot stocks" through its focus on proven medical outcomes and its breadth of products.
Hall says the company has sizeable upside as potential applications for its product include not only pain treatments but also other chronic health issues such as Type II Diabetes and depression.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE